Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 13
- Registration Number
- NCT05225805
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸University of Kansas School of Medicine, Kansas City, Kansas, United States
PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)
- Conditions
- Pediatric ALL
- Interventions
- Drug: ZTI-01 100 mg/kgDrug: ZTI-01 75 mg/kg
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT03709914
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸University of New Mexico Hospital, Albuquerque, New Mexico, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
4-way Crossover QT Evaluation in Healthy Subjects
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 41
- Registration Number
- NCT03709927
- Locations
- 🇺🇸
Pharmaron, Baltimore, Maryland, United States
A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781
- Conditions
- Healthy
- Interventions
- Drug: BC-3781
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 10
- Registration Number
- NCT03131141
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
- Conditions
- Community Acquired Pneumonia
- Interventions
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 738
- Registration Number
- NCT02813694
- Locations
- 🇺🇸
Site 1060, Houston, Texas, United States
🇺🇸Site 1065, Fresno, California, United States
🇺🇸Site 1069, Houston, Texas, United States
Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
- Conditions
- Urinary Tract Infection SymptomaticUrinary Tract Infection ComplicatedAcute Pyelonephritis
- Interventions
- Drug: ZTI-01Drug: Piperacillin-tazobactam
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 465
- Registration Number
- NCT02753946
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
- Conditions
- Community Acquired Pneumonia
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 551
- Registration Number
- NCT02559310
- Locations
- 🇦🇷
Site 3005, La Plata, Buenos Aires, Argentina
🇦🇷Site 3007, Córdoba, Argentina
🇦🇷Site 3001, Córdoba, Argentina
Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 20
- Registration Number
- NCT02557789
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 210
- Registration Number
- NCT01119105
- Locations
- 🇺🇸
BC-3781 Study Center 002, Chula Vista, California, United States
🇺🇸BC-3781 Study Center 003, Oceanside, California, United States
🇺🇸BC-3781 Study Center 012, Columbus, Georgia, United States